Peptides by condition · Weight, blood sugar, liver and gut
Peptides studied for chronic constipation and IBS-C
Checked against our study pages and the FDA labelsPublished by PepVault
Our library holds 4 study pages on chronic constipation and IBS-C: 4 in people (all meta-analyses or randomized trials). They studied one compound, Linaclotide.
What the research on chronic constipation and IBS-C looks like
Chronic constipation means bowel movements that are hard, rare or difficult to pass for months at a time. When belly pain comes with it, doctors call it irritable bowel syndrome with constipation, or IBS-C. The peptide studied here, linaclotide, stays in the gut: it switches on a receptor in the gut lining that draws water into the bowel, so stool turns softer and moves faster. Because almost none of it is absorbed into the blood, its effects and its side effects stay mostly in the bowel. Linaclotide is also used before a colonoscopy, added to the drink that empties the bowel; those studies are about preparing the bowel rather than constipation, so they are not on this page.
Constipation trials count spontaneous bowel movements each week, the ones that come without a laxative, and ask people to rate straining, stool form and belly pain in a daily diary, against a placebo group. A responder is usually someone who met a set rise in those weekly movements for most of the weeks of the trial, and the trials in children used the same diary kept with a parent.
Constipation and belly pain respond to placebo, so the comparison with a placebo group matters most. Diarrhea is the side effect to watch. Trials in children and in adults were run separately, and a result in one group does not carry over to the other. Look at how long each trial ran too: a few weeks shows whether the drug acts, while months show whether the effect holds and whether people keep taking it.

The 4 studies, by compound
Grouped by the compound each study is filed under, and within each, strongest design first. Each line gives the design, who was studied, how many and the year, before the finding.
Linaclotide
4 in peopleFor chronic constipation and IBS-C, 4 of our study pages are filed under Linaclotide: 1 meta-analysis and 3 randomized trials in people. The largest in people enrolled 1,276 people and was published in 2011. They were published from 2011 to 2024, in Clin Gastroenterol Hepatol, N Engl J Med, Lancet Gastroenterol Hepatol and J Pediatr Gastroenterol Nutr.
FDA-approved, with a use tied to chronic constipation and IBS-C on its label: Linzess (capsule) for irritable bowel syndrome with constipation (adults and children 7 and older), chronic constipation with no known cause in adults, and functional constipation in children 2 and older.
- Meta-analysis in people · 2013Linaclotide beat placebo in IBS-C and chronic constipation trials
- Randomized trial in people · 1,276 people · 2011Linaclotide beat placebo for chronic constipation in 12-week trials
- Randomized trial in people · 330 people · 2024Linaclotide raised weekly bowel movements in kids with constipation
- Randomized trial in people · 173 people · 2024Linaclotide: trend to more bowel movements in kids at higher doses
Side by side
For the compound on this page: studies in people, studies in animals or cells, the size of the largest study in people, and the FDA status from the labels our status pages read (a dash where they hold no record).
| Compound | In people | Animals or cells | Largest in people | FDA |
|---|---|---|---|---|
| Linaclotide | 4 | 0 | 1,276 | Approved, a use tied to it |
- In people
- 4
- Animals or cells
- 0
- Largest in people
- 1,276
- FDA
- Approved, a use tied to it
What the studies did not show
Each study page names its own limits. These are the questions still open, in the study pages’ words.
- Linaclotide beat placebo for chronic constipation in 12-week trialsEach trial lasted only 12 weeks, so long-term risks and benefits were not tested. The trials were funded by Ironwood Pharmaceuticals and Forest Research Institute.
- Linaclotide raised weekly bowel movements in kids with constipationThe trial lasted 12 weeks and tested a single dose, so it does not show longer-term effects or how other doses compare. It was funded by AbbVie and Ironwood Pharmaceuticals.
This page is a reading of published studies, not medical advice. A diagnosis, and what to do about it, is a conversation with a clinician.
Questions
Which peptides have been studied for chronic constipation and IBS-C?
Our 4 study pages on chronic constipation and IBS-C are all filed under one compound, Linaclotide.
Have any been tested in people with chronic constipation and IBS-C?
Yes: all 4 were in people, all of them meta-analyses or randomized trials (Linaclotide). The largest enrolled 1,276 people: “Linaclotide beat placebo for chronic constipation in 12-week trials” (2011).
Is any peptide FDA-approved for chronic constipation and IBS-C?
Yes, with a use tied to chronic constipation and IBS-C on their FDA labels: Linaclotide as Linzess. Every compound here is.
How large were the studies in people on chronic constipation and IBS-C?
Of the 4 in people, 3 give their size on our pages: 1 had 1,000 people or more and 2 had 100 to 999. The largest, a randomized trial from 2011, enrolled 1,276.
What is the newest study on chronic constipation and IBS-C here?
Of our study pages on chronic constipation and IBS-C, the newest is “Linaclotide raised weekly bowel movements in kids with constipation”, a randomized trial in people published in 2024.
How this page was built
A study page is listed here only where we read its question, design and finding and the study was about this condition: its subjects had the condition, or were an animal or cell model of it, and the study gave them the compound. A study that only mentions the condition is not listed.
Studies are grouped by the compound each is filed under and ordered by design: meta-analyses and randomized trials in people first, then other studies in people, then animals, then cells, and within a group by size and then by year. The FDA status comes from the labels our legal-status and brand pages read.